WebMay 3, 2024 · Parsippany, NJ, May 03, 2024 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) announced today that … WebMar 31, 2024 · The Interpace Diagnostics molecular testing platforms ThyGeNEXT and ThyraMIR possess a high NPV (95%) and are used clinically to rule-out thyroid cancer . …
Did you know?
WebPARSIPPANY, NJ, Oct. 20, 2024 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG), a … WebPARSIPPANY, NJ, Sept. 01, 2024 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG), a fully integrated commercial company that provides clinically relevant molecular diagnostic tests and pathology services for improved patient diagnosis and management, today …
WebThyGeNEXT (Interpace Diagnostics, Parsippany, NJ) is a specific oncogene, mutational panel that tests genetic alterations across 10 genes associated with papillary carcinoma …
WebThyGeNEXT (Interpace Diagnostics, Parsippany, NJ) is a specific oncogene, mutational panel that tests genetic alterations across 10 genes associated with papillary carcinoma and follicular carcinoma. ThyGeNEXT uses a next generation sequencing (NGS) platform to identify genetic alterations across those 10 genes, which are as follows: ALK, BRAF, … WebPARSIPPANY, NJ, April 02, 2024 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that Medica, one of the largest health plans …
WebThe validation cohort consisted of samples from a previously reported fully blinded, multi-center, retrospective study in which combination testing with ThyGeNEXT ® + ThyraMIR … *Testing algorithm based upon Bethesda Diagnostic Categories III (AUS/FLUS) … 1. Finkelstein SD, Sistrunk JW, Malchoff CD, et al. A retrospective evaluation of … The addition of genetic analysis to the evaluation of thyroid FNA samples … Effective April 1, 2024, ThyGeNEXT ® will be billed with Proprietary Laboratory … Interpace Diagnostics is committed to providing patients with access to … Corporate Offices: 855-776-6419 Client Services: 412-224-6900 Billing: 888-963 …
WebPARSIPPANY, NJ, Oct. 20, 2024 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG), a fully integrated commercial company that provides clinically relevant molecular diagnostic tests and pathology services for improved patient diagnosis and management, today … read game suit no sukima 25WebFeb 25, 2024 · In-network status for ThyGeNEXT ® and ThyraMIR ® with State’s Largest Payer . PARSIPPANY, NJ, Feb. 25, 2024 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or “the Company”), today announced that Blue Cross Blue Shield of Illinois, owned by Health Care Services Corporation (HCSC) and the largest health plan in … dupla gian e giovani hojeWebMar 27, 2024 · Q4 Revenue of $8.3 million Cash and Cash Equivalents total $4.8 million as of December 31, 2024 PARSIPPANY, NJ, March 27, 2024 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the fiscal year and fourth quarter ended December 31, … read gokinjo monogatari onlineWebAug 17, 2024 · Four molecular tests are now commercially available to provide a clearer cytological assessment of thyroid tumors: Afirma (Veracyte), ThyroSeq (CBLPath), … read gd\u0026tWebThis study aimed to examine whether concurrent mutations with a TERT promoter mutation are associated with a greater likelihood of more aggressive disease than a TERT promoter mutation alone. The medical records of 1477 patients who underwent thyroid surgery at two tertiary hospitals between 2024 and 2024 were reviewed. Twenty-four patients had … read file object javaWeb0245U ThyGeNEXT (Interpace Diagnostics) Thyroid Cancer Diagnostic Algorithmic Tests C73, D44.0, E04.1 0018U ThyraMIR (Interpace Diagnostics) Thyroid Cancer Diagnostic … dupla h\u0026mWebMay 14, 2024 · Interpace Diagnostics said it is launching ThyGeNext, a mutational panel for indeterminate thyorid nodules, at the American Association of Clinical … read.gov